查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1700104

2032 年SEVOFLURANE市场预测：按产品、配方、分销管道、应用、最终用户和地区进行的全球分析

Sevoflurane Market Forecasts to 2032 - Global Analysis by Product (Generic Sevoflurane and Branded Sevoflurane), Formulation, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球SEVOFLURANE市场预计在 2025 年达到 4.761 亿美元，到 2032 年将达到 7.399 亿美元，预测期内的复合年增长率为 6.5%。

SEVOFLURANE是一种挥发性吸入麻醉剂，广泛用于全身麻醉的诱导和维持。它是一种无色、不易燃的液体，具有甜味，非常适合儿科和成人患者使用。SEVOFLURANE以其快速的麻醉起效和恢復而闻名，它可以最大限度地减少呼吸道刺激并实现平稳的麻醉诱导。较低的血气分配係数可以快速调整麻醉深度。它通常耐受性良好，但可能导致剂量相关性低血压，并且罕见地导致肾毒性。

根据2021年出版的《世界外科杂誌》报道，印度进行了3,646例手术，以满足民众的手术需求。

增加外科手术

全球外科手术数量的增加推动了SEVOFLURANE市场的显着成长。SEVOFLURANE是一种常用的吸入麻醉剂，因其诱导和恢復时间快，在医院和门诊手术中心使用。由于慢性病发病率上升、微创手术的改进以及更大规模医疗保健系统的发展，需求也在增长。由于人口老化导致外科手术需求增加，SEVOFLURANE在现代麻醉实践中的重要作用得到了不断扩大的市场的进一步支持。

与其他方案相比高成本

与其他麻醉剂相比，SEVOFLURANE的高成本是市场成长的主要障碍。医疗机构，尤其是在成本敏感地区的医疗机构，可能会选择Isoflurane或DESFLURANE等成本较低的替代品，从而限制SEVOFLURANE的采用。这种成本障碍将影响采购决策，尤其是在新兴市场，进而降低整体需求。此外，SEVOFLURANE的使用可能会在对价格敏感的医院和诊所受到限制，从而影响製造商的销售和收益成长。

麻醉技术的进展

麻醉技术的进步提高了患者的安全性、准确性和手术效率，从而推动了市场的显着成长。自动麻醉输送、即时监控和低流量技术等创新优化了SEVOFLURANE的使用，减少了浪费和副作用。微创手术的兴起和汽化器的改进进一步推动了需求。此外，改善的药物动力学和恢復情况使SEVOFLURANE成为麻醉师的首选。总的来说，这些进步正在推动市场扩张，使全球麻醉服务更加安全、有效。

潜在的副作用

SEVOFLURANE市场面临监管限制、供应链中断和健康问题的潜在负面影响。有关挥发性麻醉剂的严格环境法规阻碍了市场扩张。供应链不稳定，包括原料短缺，将影响生产和定价。此外，对儿童和老年人神经毒性的担忧引发了安全问题，导致采用率低。来自替代麻醉剂的竞争日益激烈以及对全身静脉麻醉 (TIVA) 的日益偏好进一步限制了市场的成长和盈利。

COVID-19的影响：

COVID-19 疫情对SEVOFLURANE市场产生了各种影响。虽然封锁导致择期手术减少，但重症患者（尤其是新冠肺炎患者）的机械通气对SEVOFLURANE的需求却大幅增加。虽然供应链中断和医院资源重新分配最初减缓了市场成长，但疫情后的復苏、外科手术的增加以及医疗基础设施的改善正在推动整个行业需求的强劲復苏。

预计预测期内医院部门将实现最大幅度成长。

预计医院部门将在预测期内占据最大的市场占有率，因为医院是外科手术麻醉剂的主要使用者。手术量的增加、医疗基础设施的改善以及麻醉技术的进步正在推动医院对SEVOFLURANE的需求。此外，需要手术介入的慢性病的盛行率不断上升也推动了市场的成长。由于其功效、安全性和在全身麻醉中的广泛应用，该领域得到了广泛的应用，增强了对市场扩张的正面影响。

预计高纯度SEVOFLURANE市场在预测期内的复合年增长率最高

在预测期内，高纯度SEVOFLURANE部分预计将呈现最高的成长率，因为它在麻醉应用中具有卓越的功效、安全性和减少的副作用。随着外科手术的增加和对微创治疗的需求不断增长，医院和诊所优先考虑高纯度配方以改善患者的治疗效果。此外，严格的监管标准和药品製造的进步确保了始终如一的质量，进一步促进了市场采用。

比最大的地区

在预测期内，由于外科手术的增加、麻醉剂的技术发展以及医疗保健支出的增加，预计北美将占据最大的市场占有率。SEVOFLURANE因其有效性、恢復时间短、副作用少而被推荐为吸入性麻醉剂。人口老化和慢性病的增加也在推动需求。麻醉剂输送技术的持续研究和开发进一步推动了它的普及。市场扩张正在刺激该地区尖端医疗保健基础设施的发展，确保患者获得更好的治疗结果。

复合年增长率最高的地区：

预计亚太地区在预测期内的复合年增长率最高。这是由于外科手术的增加、医疗保健基础设施的成长以及麻醉剂技术的突破。透过提供更安全、更有效的吸入麻醉剂，市场正在改善患者的治疗效果。人口老化、医疗旅游成长和医院发展进一步推动了需求。SEVOFLURANE对于提高外科手术效果和一般医疗保健标准起着重要作用，而政府改善医疗保健机会的计划也支持了市场成长。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场公司（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球SEVOFLURANE市场（按产品）

  • 非专利SEVOFLURANE
  • 品牌SEVOFLURANE

6. 全球SEVOFLURANE市场（依配方）

  • 标准纯度SEVOFLURANE
  • 高纯度SEVOFLURANE

7. 全球SEVOFLURANE市场（依分销管道）

  • 直销
  • 分销商/批发商
  • 网路药局
  • 零售药局

8. 全球SEVOFLURANE市场（依应用）

  • 麻醉诱导
  • 麻醉维持

9. 全球SEVOFLURANE市场（依最终用户）

  • 医院
  • 门诊手术中心（ASC）
  • 专科诊所
  • 其他医疗机构

第 10 章全球SEVOFLURANE市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • AbbVie Inc.
  • Accord Healthcare
  • AstraZeneca
  • Baxter International Inc.
  • Beijing Zizhu Pharmaceutical Co., Ltd.
  • Endo International plc
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Hospira Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Lunan Pharmaceutical Group Co., Ltd.
  • Maruishi Pharmaceutical Co., Ltd.
  • Merck KGaA
  • Piramal Critical Care
  • Shandong Keyuan Pharmaceutical Co., Ltd.
  • Shanghai Huayuan Ethylene Co., Ltd.
  • Troikaa Pharmaceuticals Ltd. .
Product Code: SMRC29007

According to Stratistics MRC, the Global Sevoflurane Market is accounted for $476.1 million in 2025 and is expected to reach $739.9 million by 2032 growing at a CAGR of 6.5% during the forecast period. Sevoflurane is a volatile, inhalational anesthetic widely used for inducing and maintaining general anesthesia. It is a colorless, non-flammable liquid with a sweet odor, making it ideal for pediatric and adult patients. Known for its rapid onset and recovery, sevoflurane provides smooth induction with minimal airway irritation. It has a low blood-gas partition coefficient, allowing quick adjustments in anesthesia depth. While generally well-tolerated, it can cause dose-dependent hypotension and rare nephrotoxicity.

According to the World Journal of Surgery published in 2021, 3646 operations were conducted to satisfy the surgical requirements of the population in India.

Market Dynamics:

Driver:

Increasing Surgical Procedures

The growing number of surgical procedures worldwide is propelling considerable growth in the sevoflurane market. Sevoflurane is a popular inhalation anesthetic that is used in hospitals and ambulatory surgery centers due to its quick induction and recovery times. Demand is also being increased by the growing incidence of chronic illnesses, improvements in less invasive surgery, and the development of a larger healthcare system. Sevoflurane's vital function in contemporary anesthetic methods is further supported by the market's expansion due to the aging population's increased need for surgical procedures.

Restraint:

High Cost Compared to Alternatives

The high cost of sevoflurane compared to alternative anesthetics significantly hinders its market growth. Healthcare facilities, especially in cost-sensitive regions, may opt for lower-cost substitutes like isoflurane or desflurane, limiting sevoflurane adoption. This cost barrier affects procurement decisions, particularly in developing markets, reducing its overall demand. Additionally, price-conscious hospitals and clinics may restrict its usage, impacting sales and revenue growth for manufacturers.

Opportunity:

Advancements in Anesthesia Technology

Advancements in anesthesia technology are driving significant growth in the market, enhancing patient safety, precision, and efficiency in surgeries. Innovations such as automated anesthesia delivery, real-time monitoring, and low-flow techniques optimize Sevoflurane usage, reducing wastage and side effects. The rise of minimally invasive procedures and improved vaporizers further boost demand. Additionally, enhanced pharmacokinetics and better recovery profiles make Sevoflurane the preferred choice for anesthetists. These advancements collectively fuel market expansion, ensuring safer and more effective anesthesia administration worldwide.

Threat:

Potential Adverse Effects

The Sevoflurane market faces potential adverse effects due to regulatory restrictions, supply chain disruptions, and health concerns. Stringent environmental regulations on volatile anesthetics hinder market expansion. Supply chain volatility, including shortages of raw materials, affects production and pricing. Additionally, concerns over neurotoxicity in pediatric and elderly patients raise safety issues, leading to reduced adoption. Rising competition from alternative anesthetics and increasing preference for total intravenous anesthesia (TIVA) further restrict market growth and profitability.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the sevoflurane market. While elective surgeries declined due to lockdowns, the demand for Sevoflurane surged in critical care settings, particularly for ventilated COVID-19 patients. Supply chain disruptions and hospital resource reallocation initially slowed market growth, but post-pandemic recovery, increased surgical procedures, and improved healthcare infrastructure have driven a strong resurgence in demand across the industry.

The hospitals segment is expected to be the largest during the forecast period

The hospitals segment is expected to account for the largest market share during the forecast period as these facilities are primary users of the anesthetic for surgical procedures. With rising surgical volumes, increasing healthcare infrastructure, and advancements in anesthesia techniques, hospitals are boosting demand for Sevoflurane. Additionally, the growing prevalence of chronic diseases requiring surgical interventions further fuels market growth. The segment benefits from strong adoption due to its effectiveness, safety profile, and widespread use in general anesthesia, reinforcing its positive impact on market expansion.

The high purity sevoflurane segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the high purity sevoflurane segment is predicted to witness the highest growth rate due to its superior efficacy, safety, and reduced side effects in anesthesia applications. With increasing surgical procedures and rising demand for minimally invasive treatments, hospitals and clinics are prioritizing high-purity formulations for better patient outcomes. Additionally, stringent regulatory standards and advancements in pharmaceutical manufacturing are ensuring consistent quality, further boosting market adoption.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to an increase in surgical operations, technological developments in anesthetic, and growing healthcare expenditures. Sevoflurane is the recommended option for inhalation anesthetic because to its effectiveness, quick recovery period, and few side effects. Demand is also fueled by an aging population and the rising incidence of chronic diseases. Its popularity is further aided by continuous research and development in anesthetic administration technologies. This market expansion adds to the region's cutting-edge healthcare infrastructure and guarantees better patient results.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR because of an increase in surgical operations, a growing healthcare infrastructure, and technological breakthroughs in anesthetic. By offering safer and more effective inhalation anesthetic, the market is improving patient outcomes. Demand is further fueled by an aging population, growing medical tourism, and hospital development. Sevoflurane is a major factor in raising surgical effectiveness and general healthcare standards in the area, and government programs to improve healthcare accessibility also support market growth.

Key players in the market

Some of the key players in Sevoflurane Market include AbbVie Inc., Accord Healthcare, AstraZeneca, Baxter International Inc., Beijing Zizhu Pharmaceutical Co., Ltd., Endo International plc, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Hospira Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lunan Pharmaceutical Group Co., Ltd., Maruishi Pharmaceutical Co., Ltd., Merck KGaA, Piramal Critical Care, Shandong Keyuan Pharmaceutical Co., Ltd., Shanghai Huayuan Ethylene Co., Ltd. and Troikaa Pharmaceuticals Ltd.

Key Developments:

In March 2025, AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme(TM) platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets.

In February 2024, AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

Products Covered:

  • Generic Sevoflurane
  • Branded Sevoflurane

Formulations Covered:

  • Standard Purity Sevoflurane
  • High Purity Sevoflurane

Distribution Channels Covered:

  • Direct Sales
  • Distributors/Wholesalers
  • Online Pharmacies
  • Retail Pharmacies

Applications Covered:

  • Induction of Anesthesia
  • Maintenance of Anesthesia

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Specialty Clinics
  • Other Healthcare Facilities

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Sevoflurane Market, By Product

  • 5.1 Introduction
  • 5.2 Generic Sevoflurane
  • 5.3 Branded Sevoflurane

6 Global Sevoflurane Market, By Formulation

  • 6.1 Introduction
  • 6.2 Standard Purity Sevoflurane
  • 6.3 High Purity Sevoflurane

7 Global Sevoflurane Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct Sales
  • 7.3 Distributors/Wholesalers
  • 7.4 Online Pharmacies
  • 7.5 Retail Pharmacies

8 Global Sevoflurane Market, By Application

  • 8.1 Introduction
  • 8.2 Induction of Anesthesia
  • 8.3 Maintenance of Anesthesia

9 Global Sevoflurane Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Ambulatory Surgical Centers (ASCs)
  • 9.4 Specialty Clinics
  • 9.5 Other Healthcare Facilities

10 Global Sevoflurane Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Inc.
  • 12.2 Accord Healthcare
  • 12.3 AstraZeneca
  • 12.4 Baxter International Inc.
  • 12.5 Beijing Zizhu Pharmaceutical Co., Ltd.
  • 12.6 Endo International plc
  • 12.7 Fresenius Kabi AG
  • 12.8 Hikma Pharmaceuticals PLC
  • 12.9 Hospira Inc.
  • 12.10 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 12.11 Lunan Pharmaceutical Group Co., Ltd.
  • 12.12 Maruishi Pharmaceutical Co., Ltd.
  • 12.13 Merck KGaA
  • 12.14 Piramal Critical Care
  • 12.15 Shandong Keyuan Pharmaceutical Co., Ltd.
  • 12.16 Shanghai Huayuan Ethylene Co., Ltd.
  • 12.17 Troikaa Pharmaceuticals Ltd. .

List of Tables

  • Table 1 Global Sevoflurane Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 4 Global Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 5 Global Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 6 Global Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 7 Global Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 8 Global Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 9 Global Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 10 Global Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 11 Global Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 12 Global Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 13 Global Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 14 Global Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 15 Global Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 16 Global Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 17 Global Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 18 Global Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 19 Global Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 20 Global Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 21 North America Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 22 North America Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 23 North America Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 24 North America Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 25 North America Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 26 North America Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 27 North America Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 28 North America Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 29 North America Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 30 North America Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 31 North America Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 32 North America Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 33 North America Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 34 North America Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 35 North America Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 36 North America Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 37 North America Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 38 North America Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 39 North America Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 40 North America Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 41 Europe Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 42 Europe Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 43 Europe Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 44 Europe Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 45 Europe Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 46 Europe Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 47 Europe Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 48 Europe Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 49 Europe Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 50 Europe Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 51 Europe Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 52 Europe Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 53 Europe Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 54 Europe Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 55 Europe Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 56 Europe Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 57 Europe Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 58 Europe Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 59 Europe Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 60 Europe Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 61 Asia Pacific Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 62 Asia Pacific Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 63 Asia Pacific Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 64 Asia Pacific Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 65 Asia Pacific Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 66 Asia Pacific Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 67 Asia Pacific Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 68 Asia Pacific Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 69 Asia Pacific Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 70 Asia Pacific Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 71 Asia Pacific Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 72 Asia Pacific Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 73 Asia Pacific Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 74 Asia Pacific Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 75 Asia Pacific Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 76 Asia Pacific Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 77 Asia Pacific Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 78 Asia Pacific Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 79 Asia Pacific Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 80 Asia Pacific Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 81 South America Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 82 South America Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 83 South America Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 84 South America Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 85 South America Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 86 South America Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 87 South America Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 88 South America Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 89 South America Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 90 South America Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 91 South America Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 92 South America Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 93 South America Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 94 South America Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 95 South America Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 96 South America Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 97 South America Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 98 South America Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 99 South America Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 100 South America Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 101 Middle East & Africa Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 102 Middle East & Africa Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 103 Middle East & Africa Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 104 Middle East & Africa Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 105 Middle East & Africa Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 106 Middle East & Africa Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 107 Middle East & Africa Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 108 Middle East & Africa Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 109 Middle East & Africa Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 110 Middle East & Africa Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 111 Middle East & Africa Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 112 Middle East & Africa Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 113 Middle East & Africa Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 114 Middle East & Africa Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 115 Middle East & Africa Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 116 Middle East & Africa Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 117 Middle East & Africa Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 118 Middle East & Africa Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 119 Middle East & Africa Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 120 Middle East & Africa Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)